AstraZeneca Recalls 1 Lot of Brilinta

FDA says that AstraZeneca is recalling one specific lot of its Brilinta (ticagrelor) 90 mg tablets 8-count physician sample bottles following reports that a professional sample bottle containing eight tablets of Brilinta also contained AZ’s Zurampic (lesinurad) 200 mg tablets. The agency notice says that unintentional dosing with Zurampic has the potential to lead to adverse renal effects, including acute renal failure, which is more common when Zurampic is given alone.

Brilinta is indicated to reduce the rate of cardiovascular death, heart attack, and stroke in patients with acute coronary syndrome or a history of heart attack. Zurampic is used with a xanthine oxidase inhibitor such as allopurinol or Uloric in adults with gout who still have a high uric acid level.

The company says that other forms and dosage strengths of Brilinta are not affected by the recall.